产品
编 号：F238539
分子式：C10H21Cl2N3OS
分子量：302.26
分子式：C10H21Cl2N3OS
分子量：302.26
产品类型
规格
价格
是否有货
5mg
250
In-stock
10mg
400
In-stock
50mg
1200
In-stock
结构图
CAS No: 191217-81-9
产品详情
生物活性：
Pramipexole dihydrochloride hydrate is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride hydrate can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS).
体内研究：
Pramipexole dihydrochloride hydrate (0.25-1 mg/kg; i.p.) significantly reduces the infarction volume in animals.Pramipexole dihydrochloride hydrate improves neurological recovery.Pramipexole dihydrochloride hydrate prevents ischemic cell death via mitochondrial pathways in ischemic stroke.Animal Model:Male Wistar rats weighing 250-300 g (16-18 weeks old)
Dosage:0.25 mg/kg, 1 mg/kg
Administration:Intraperitoneal injection
Result:Decreased infarction volume as compared to tMCAO (transient middle cerebral artery occlusion)-only animals.
体外研究：
Pramipexole dihydrochloride hydrate shows a low binding affinity for D1-type receptor, with an IC50 of >50,000 nM.Pramipexole dihydrochloride hydrate (0.01-10?μM; 72 hours) produces dose-dependent increases of dendritic arborization and soma size.Pramipexole dihydrochloride hydrate attenuates levodopa-induced toxicity in mesencephalic cultures.
Pramipexole dihydrochloride hydrate is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride hydrate can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS).
体内研究：
Pramipexole dihydrochloride hydrate (0.25-1 mg/kg; i.p.) significantly reduces the infarction volume in animals.Pramipexole dihydrochloride hydrate improves neurological recovery.Pramipexole dihydrochloride hydrate prevents ischemic cell death via mitochondrial pathways in ischemic stroke.Animal Model:Male Wistar rats weighing 250-300 g (16-18 weeks old)
Dosage:0.25 mg/kg, 1 mg/kg
Administration:Intraperitoneal injection
Result:Decreased infarction volume as compared to tMCAO (transient middle cerebral artery occlusion)-only animals.
体外研究：
Pramipexole dihydrochloride hydrate shows a low binding affinity for D1-type receptor, with an IC50 of >50,000 nM.Pramipexole dihydrochloride hydrate (0.01-10?μM; 72 hours) produces dose-dependent increases of dendritic arborization and soma size.Pramipexole dihydrochloride hydrate attenuates levodopa-induced toxicity in mesencephalic cultures.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备